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 Abstract 
Patients with a Zellweger spectrum disorder (ZSD) have a defect in the assembly or 
maintenance of peroxisomes, leading to a multisystem disease with variable outcome. 
Liver disease is an important feature in patients with severe and milder phenotypes and a 
frequent cause of death. However, the course and histology of liver disease in ZSD 
patients are ill-defined. We reviewed the hepatic symptoms and histological findings of 
13 patients with a ZSD in which one or several liver biopsies have been performed 
(patient age 0.2-39 years). All patients had at least some histological liver abnormalities, 
ranging from minor fibrosis to cirrhosis. Five patients demonstrated significant disease 
progression with liver failure and early death. In others, liver related symptoms were 
absent, although some still silently developed cirrhosis. Patients with peroxisomal 
mosaicism had a better prognosis. In addition, we show that patients are at risk to develop 
a hepatocellular carcinoma (HCC), as one patient developed a HCC at the age of 36 years 
and one patient a precancerous lesion at the age of 18 years. Thus, regular examination to 
detect fibrosis or cirrhosis should be included in the standard care of ZSD patients. In 
case of advanced fibrosis/cirrhosis expert consultation and HCC screening should be 
initiated. This study further delineates the spectrum and significance of liver involvement 
in ZSDs.  
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 Take-home message:  Liver fibrosis and cirrhosis with or without clinical symptoms of 
liver disease is already present at a very young age in patients with a Zellweger spectrum 
disorder and they are at increased risk to develop a hepatocellular carcinoma.  
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 Abbreviations 
DHCA  Dihydroxycholestanoic acid 
HCC  Hepatocellular carcinoma  
H&E  Hematoxylin and eosin 
PBD  Peroxisome biogenesis disorder 
THCA  Trihydroxycholestanoic acid 
VLCFA Very long-chain fatty acids 
ZSD  Zellweger spectrum disorders 
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 1. Introduction 
Zellweger spectrum disorders (ZSDs) are autosomal recessive disorders with a deficiency 
of functional peroxisomes caused by mutations in one of the peroxisome assembly (PEX) 
genes (Waterham and Ebberink 2012). Biochemically, the most prominent features are 
the accumulation of bile acid intermediates (i.e. dihydroxycholestanoic acid (DHCA) and 
trihydroxycholestanoic acid (THCA)), pristanic- and phytanic acid, pipecolic acid and 
very long-chain fatty acids (VLCFA) (Waterham et al. 2016). These abnormalities 
contribute to a variety of symptoms with a spectrum of severity, including developmental 
delay, hearing and vision deficits.  
In addition to neurological symptoms, liver disease is a prominent feature (Heubi 
et al. 2017) (Heubi et al. 2018) and a frequent cause of death in patient with ZSDs 
(Wanders and Ferdinandusse 2012) (Poll-The et al. 2004). Liver disease develops in all 
ZSD patients with a severe phenotype at an early age, with disease progression in the 
majority (Roels et al. 1991). Hepatic symptoms, such as hepatomegaly, cholestasis, 
elevated transaminases and liver dysfunction, usually become apparent within the first 
year of life. Despite clinical and pathological evidence of liver involvement since the 
very first reports of ZSDs, literature of histological characteristics and course of liver 
disease is scarce. Only five case reports of ZSD post-mortem studies, with the oldest 
patient being 12 years of age, highlight liver disease as one of the main ZSD features 
(Powers et al. 1985) (Gilchrist et al. 1976) (Aubourg P et al. 1986) (Chow et al. 1992) 
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 (Torvik et al. 1988). Earlier and more recent studies mentioned, in addition to absence of 
peroxisomes, other ultrastructural abnormalities such as large angulate lysosomes 
containing trilamellar inclusions (Mooi et al. 1983) (Depreter et al. 2003) (Warren et al. 
2018).    
Here, we describe the largest reported histological series of liver biopsies and/or 
reports of autopsy from 13 patients (age range from 0.2 to 39 years) to further delineate 
the spectrum and significance of liver involvement in ZSDs.  
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 2. Methods 
Material was collected at the Amsterdam University Medical Centre (Amsterdam UMC) 
and University Medical Centre Utrecht (UMCU), The Netherlands. The Amsterdam 
UMC is the centre of expertise for peroxisomal disorders in The Netherlands. For this 
study the institutional review board issued a waiver. Patients data were retrospectively 
collected by reviewing the medical records both at the Amsterdam UMC and UMCU. 
The liver biopsies were obtained between 1993 and 2004 according to in-house protocols. 
For this study, biopsies were re-examined by light microscopy using hematoxylin and 
eosin (H&E), copper staining, iron staining and collagen stainings (i.e. sirius red, Azan, 
Elastica von Giesson). Liver tissue was evaluated for the presence of steatosis. In 
addition, portal inflammation, interface activity and lobular inflammation were classified 
as: none, mild, moderate, or severe. Presence of siderosis was classified as grade 0: 
none/not observed, grade 1: ≤25% of hepatocytes, grade 2: 26–50% of hepatocytes, grade 
3: 51–75% of hepatocytes or grade 4: >75% of hepatocytes. Presence of bilirubinostasis 
and copper was evaluated. Finally, grade of fibrosis was descriptively reported, 
independent of underlying disease: (a) none, (b) perisinusoidal or periportal, (c) 
perisinusoidal and portal/periportal, or (d) bridging fibrosis, involving less than 50% of 
the portal tracts and/or central veins (e) bridging involving more than 50% of the portal 
tracts and/or central veins and (f) cirrhosis. Miscellaneous findings in biopsies, not being 
part of the initial scoring system, were also noted. All biopsies were examined by two 
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 different experienced liver pathologists (JV and MML). Electron microscopy studies and 
localisation of peroxisomal enzymes and proteins were performed as previously 
described by Roels et al (Espeel and Van Limbergen 1995) (Roels et al. 1995). 
Permission for autopsy studies for scientific purposes was obtained from the parents of 
patient 7 and 13.  
  
3. Results  
We searched our ZSD database and found reports on liver histology in 13 patients (9 
females and 4 males). Diagnosis was based on laboratory investigations to assess 
peroxisomal functions, and confirmation by enzymatic analysis in fibroblasts, and/or 
PEX gene mutation studies (Table 1). In the 13 patients with liver histology, age ranged 
from 0.2 to 39 years. Five patients are still alive. The histology includes 16 liver biopsies 
from 12 patients and 3 reports of autopsy, 2 from patients whom previously had 
undergone liver biopsies. Overviewing the neurological phenotype of these 13 patients, 
all patients had the well-known symptoms of ZSD patients, such as developmental delay, 
hearing and visual impairment and enamel hypoplasia. Zellweger severity scores 
(Klouwer et al. 2018b) and liver related symptoms are depicted in Table 1. Based on 
symptoms of liver disease we noticed two broad categories of liver phenotypes. The first 
group consisted of patients having predominant neurological symptoms, such as epilepsy 
and leukodystrophy with relatively mild and often transient symptoms and signs of liver 
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 disease, such as hepatomegaly and intermittent mildly elevated liver enzymes. Disease 
progression in this group is dominated by progression of neurological symptoms 
(Berendse et al. 2016a). Symptoms in the second group of patients are dominated by 
more severe liver related signs and symptoms, such as progressive cholestasis, severe 
coagulation defects and cirrhosis. To compare the results of hepatic histology, we divided 
our cohort in two groups based on the severity of liver related symptoms; group 1 
(patients 1-8) and group 2 (patients 9-13). Patients in group 1 presented with mild liver 
related symptoms in 5 out of 8 patients, these included prolonged neonatal jaundice 
(n=2), hepatomegaly (n=4) and hepatosplenomegaly (n=1). Three out of 8 patients had no 
liver related symptoms at time of liver biopsy. Laboratory tests in group 1 showed normal 
or only minor elevated liver enzymes. Coagulation parameters (i.e. abnormal PT, Factor 
V and VII) were mildly disturbed in all those with available data. None suffered from 
bleeding complications. Despite this mild liver phenotype, severe liver disease did 
develop in 2 patients of this group during long term follow-up. Patient 2, currently 14 
years of age, presented with transient neonatal jaundice and mainly suffered from severe 
intellectual disability since. However, at age 10 years, she developed liver cirrhosis with 
multiple regenerative nodules on imaging. Patient 7 died at the age of 36 years of 
pneumonia and respiratory failure. She never showed signs or symptoms of liver disease 
on physical, radiological and laboratory examination. However, on autopsy, the liver 
showed cirrhosis with a prominent 4 cm nodule on the external surface. Morphology 
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 showed a poorly differentiated hepatocellular carcinoma (HCC, Glypican 3 positive 
(Wang et al. 2008)).  
 Patients in group 2 suffered from a more pronounced liver phenotype.  
Three out of 5 patients presented with prolonged neonatal jaundice, 5/5 had 
hepatomegaly and splenomegaly was reported in 4/5. Except patient 13, all died before 
the age of 2 years. Patient 13 had symptoms of liver disease at the age of 8 years and died 
due to end-stage liver disease with encephalopathy, hepatorenal and hepatopulmonary 
syndrome at the age of 18 years. Autopsy of the liver showed extensive micro- and 
macronodular cirrhosis, with prominent nodules on the external surface. Negative 
immunohistochemical stainings (glutamine synthetase, beta-catenine and glypican 3) 
together with morphology suggested a dysplastic nodule and not (yet) a HCC. 
Biochemically, all patients in both groups had elevated concentrations of VLCFA 
(C26:0), DHCA and THCA in plasma. Unfortunately, phytanic- and pristanic acid levels 
in plasma and plasmalogens in erythrocytes are missing in the majority.   
 
Histological characteristics 
Findings of liver biopsy and/or autopsy are described in Table 2. Although not visible on 
light microscopy, patient 5 and 6 showed steatosis on electron microscopy. 
Bilirubinostasis was only observed in biopsies from three patients in group 2. Siderosis 
was detected in 4 biopsies (3 patients), accumulation of copper in one and portal/lobular 
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 inflammation in 13/18 samples (Figure 1 and 2). Interestingly, 7/18 biopsies showed 
remarkable presence of glycogenated nuclei and 5/18 biopsies showed abnormal bile duct 
epithelium with reactive epithelial changes. All patients, except patient 8, showed liver 
fibrosis or cirrhosis on liver biopsy/autopsy, albeit patients in group 2 had a younger age. 
In patient 5, the degree of fibrosis could not be determined due to poor quality of one 
biopsy. Overall, the fibrosis was located in perisinusoidal, periportal and/or pericellular 
space. Bridging fibrosis was seen in both groups (11/16 biopsies, Figure 1 and 2). The 
bridging fibrosis involved more than 50% of the portal tracts and/or central veins in 3/11 
biopsies. There was no differences in localization of fibrosis between the two groups. 
Follow-up biopsies showed similar degree of inflammation and fibrosis compared to the 
first biopsies (Figure 2). Sclerosis of portal areas in the absence of cirrhosis (i.e. 
hepatoportal sclerosis) was present in the biopsy of patient 8 and 11 (both groups). In 
addition to cirrhosis, we found a HCC in patient 7 and a dysplastic nodule in patient 13 at 
autopsy (Figure 1). Cytochemical localisation of peroxisomal enzymes (electron and light 
microscopy) in the liver revealed either a total absence of peroxisomes or peroxisomal 
mosaicism (i.e. a mixed population of cells with or without import competent 
peroxisomes, described in ZSD patients with a mild phenotype (Waterham and Ebberink 
2012)). Peroxisomal enzymes can localized in organelles with the morphology of 
lysosomes (Figure 3). Catalase staining on frozen sections after formaldehyde prefixation 
can reveal the presence of mosaics (Additional Figure 1). Data of peroxisomes on 
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 electron microscopy was not available for patient 7. Peroxisomal mosaicism was seen in 
5 patients, of whom 4 belong to group 1. This mosaicism is associated with longer 
survival and more benign clinical course (Roels et al. 2003). Patient 4 had, in addition to 
deficient hepatic peroxisomes, functional peroxisomes in the duodenum epithelium. 
Angulate lysosomes (with trilamellar inclusions), abundant in patients with a ZSD (Mooi 
et al. 1983), were seen in 15/18 biopsies (Figure 3). In two patients such lysosomes could 
not be found. Both died at an early age, reflecting that the typical trilamellar inclusions 
result from a storage phenomenon. 
 
4. Discussion 
Liver involvement is already reported since the very first description of ZSDs (i.e 
cerebro-hepato-renal syndrome) but the liver histology features are underreported. Here, 
we present the largest reported series of liver biopsies and reports of autopsy from 13 
patients and show that histological abnormalities range from mild fibrosis to severe 
cirrhosis in both patients with a mild and severe phenotype (group 1 and 2). Our results 
emphasize the relevance of liver disease in ZSDs with a broad spectrum of 
histomorphological findings, not only in severely affected patients (defined as patients 
with signs and symptoms of liver disease, group 2) but also in patients with mainly 
neurological symptoms that survive into adulthood (group 1). In addition to Heubi et al 
(Heubi and Bishop 2018), this study suggests that ZSD patients are at increased risk to 
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 develop a HCC based on the finding of a pre-malignant dysplastic nodule and a HCC at 
18 (patient 13) and 36 years of age (patient 7), respectively. Similar to patients with other 
inborn errors of metabolism with prolonged survival (Erez et al. 2011). 
 Bridging fibrosis was seen in 8 out of 13 patients, indicating advanced fibrosis. 
Hepatoportal sclerosis is characterized by the presence of sclerosis of portal areas in the 
absence of cirrhosis (Cantez et al. 2013). In our cohort, patients 8 and 11 suffered from 
hepatoportal sclerosis, previously described as a cause of noncirrhotic portal hypertension 
in patients with Zellweger syndrome (Schouten et al. 2011). The majority of patients had 
at least some portal and/or lobular inflammation. Glycogenated nuclei were observed in 
7/18 samples of which the clinical significance is uncertain; these nuclei can be found in 
non-alcoholic steatohepatitis, Wilsons disease, represent early hepatic injury and can be 
seen in many other disorders like diabetes mellitus, glycogen storage disorders and in 
alcohol abuse. However they also have been observed in biopsies of healthy children 
(Burt AD, Portmann BC, Ferrell LD 2006). Accumulation of copper and/or siderosis was 
found in 4 patients and is associated with chronic liver disease.  
Liver fibrosis is potentially reversible, but when progressed to cirrhosis the 
disease is mostly irreversible (Tsochatzis et al. 2014). The most severe, and possibly 
fatal, complications of liver cirrhosis are oesophageal variceal bleeding due to portal 
hypertension, hepatopulmonary syndrome, hepatorenal syndrome, hepatic 
encephalopathy and coagulation defects due to liver failure (Tsochatzis et al. 2014) 
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 (Fattovich et al. 2004) (Amitrano et al. 2002). Patients are also at risk to develop a HCC 
(Fattovich et al. 2004). Hepatoportal sclerosis, present in 2 patients, is also a risk factor 
for portal hypertension and oesophageal variceal bleeding. These findings illustrate the 
importance of early intervention to prevent the development of fibrosis or the progression 
of fibrosis to cirrhosis and associated complications. Cholic acid was shown to lower 
toxic bile acid intermediates in plasma in patients with a mild phenotype (Berendse et al. 
2016b). It was hypothesis that cholic acid therapy could prevent disease progression and 
progression of liver disease. However, short- and long-term follow-up showed, besides 
significant increase in weight, no improvement of clinical symptoms or liver phenotype 
(Klouwer et al. 2018a)(Heubi et al. 2018). Long-term follow-up did show stabilization of 
liver function/enzymes (Heubi et al. 2018). However, if the stabilization of liver function 
was caused by cholic acid supplementation and not by natural course of disease is 
unknown due to missing data of natural history of liver phenotype in ZSDs. Liver 
transplantation could be a therapeutic option in end stage liver failure. Only few case 
reports of liver transplantation in ZSDs are published. These studies showed 
normalisation of phytanic acid, pristanic acid and pipecolic acid in plasma after liver 
transplantation. Unfortunately, detailed data of C27-bile acid intermediates is missing 
(Matsunami et al. 2016)  (Demaret et al. 2018).  
A possible cause of the liver abnormalities are the C27-bile acid intermediates (i.e. 
DHCA and THCA), which were increased in all patients (in group 1 and 2). Due to 
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 impaired bile acid synthesis, these intermediates accumulate in plasma and organs of 
ZSD patients. They are considerably more toxic than physiological C24-bile acids, cholic- 
and chenodeoxycholic acid (Ferdinandusse et al. 2009a). Furthermore, they are less 
efficiently excreted from the hepatocytes into the bile ducts leading to cholestasis 
(Ferdinandusse et al. 2009b). Unfortunately, because detailed data of these intermediates 
are missing in several patients of this study, a correlation between the levels of 
intermediates and the severity of histological abnormalities in both groups could not be 
investigated and has to be studied in a prospective natural history study. Supporting the 
hypothesis of a hepatotoxic effect of C27-bile acid intermediates, is the finding of liver 
fibrosis in patients with single peroxisomal enzyme deficiencies, other disorders in which 
these C27-bile acid intermediates accumulate. These diseases include D-bifunctional 
protein deficiency (DBP) deficiency (Ferdinandusse et al. 2006), acyl-CoA oxidase 2 
(ACOX2) (Vilarinho et al. 2016), ATP-binding cassette transporters 3 (ABCD3) 
(Ferdinandusse et al. 2015) and alpha-methylacyl-CoA racemase (AMACR) deficiency 
(Setchell et al. 2003)  
Besides patients, mouse models also give insight into the pathophysiology and 
potential oncogenesis of liver disease in ZSD. An interesting model is the AMACR 
mouse, in which C27-bile acid intermediates accumulate. Surprisingly, knockout mice 
have normal survival and no hepatic phenotype (i.e. normal histology) (Savolainen et al. 
2004). When such mice are fed phytol (a precursor of phytanic acid) elevated levels of 
 
 
This article is protected by copyright. All rights reserved.
 phytanic and pristanic acid can be found and mice develop a liver phenotype with 
inflammation and fibrosis (Selkälä et al. 2015). Suggesting that accumulation of bile acid 
intermediates alone is not sufficient to cause liver injury and a liver phenotype. In 
addition, isolated phytanic acid accumulation is not sufficient to develop a liver disease 
either, as illustrated by patients with Refsum disease who have no liver phenotype 
(Wanders and Ferdinandusse 2012).  In contrast to the AMACR model, mouse models 
for peroxisomal biogenesis disorders are associated with a liver phenotype including 
hepatomegaly, cholestasis and liver fibrosis (for a comprehensive review see (Baes and 
Van Veldhoven 2016)). In a mouse model with complete knock-out of functional 
peroxisomes and accumulation of peroxisomal metabolites (i.e. PEX5), an upregulation 
of C-myc in liver has been reported (Peeters et al. 2015). C-myc is a known proto-
oncogene involved in cancer metabolism that also plays a crucial role in the pathogenesis 
of HCCs (Lin et al. 2010). C-myc can be induced by activation of the nuclear receptor 
peroxisome proliferator-activated receptor alpha (PPARα) (Gonzalez and Shah 2008). In 
humans, bile acids have been shown to activate PPARα (Pineda Torra et al. 2003) and 
can thus potentially also activate C-myc (Li and Chiang 2009). It would be interesting to 
measure expression of C-myc in liver biopsies of our patients.  
Limitations of our study include the possible sample error associated with needle 
liver biopsies. All biopsies were examined by the same liver pathologists to exclude and 
minimize the inter- and intra-observer variation. Furthermore, because of the 
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 retrospective character of the study with some patients living in the early 90’s, detailed 
clinical features (including use of medication) and biochemical parameters are missing.  
In view of the high risk for ZSD patients to develop liver cirrhosis, even in the 
absence of liver related symptoms, and increased risk of HCC monitoring of and 
counselling on liver disease is warranted. To provide comprehensive supportive 
management for ZSD patients and other peroxisomal diseases associated with liver 
disease, we advise to include yearly screening for liver fibrosis by either ultrasound, 
preferably combined with elastography given its superior accuracy to diagnose fibrosis. 
When signs of significant liver fibrosis or HCC develop, a paediatric gastroenterologist 
should be consulted. When cirrhosis is diagnosed, patients should be counselled on the 
risk of decompensation of cirrhosis and the development of a HCC. Most importantly, the 
risk of variceal bleeding and the pros and cons of oesophageal varices screening should 
be discussed not only in patient with cirrhosis but also in patients with signs of portal 
hypertension in the absence of cirrhosis (e.g.due to hepatoportal sclerosis). Although the 
exact risk of HCC in Zellweger is unknown, it is presumably high based on two HCC 
cases (Heubi and Bishop 2018 and this study) in this rare disorder. In view of this risk, 
HCC surveillance by performing an ultrasound should be considered in ZSD patients 
with cirrhosis at the discretion of a consulting hepatologist. However, the decision to 
screen for HCC can only be made on individual basis and in consultation with the 
guardians and patient. Aspects that should be weighted are the burden of performing 
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 ultrasounds and additional testing if suspicion lesions are found, the anxiety screening 
can cause and the limited treatment options in these severely affected patients with an 
often limited life expectancy. It remains to be established whether ZSD patients without 
cirrhosis are at increased risk of developing HCC and whether screening in this group 
should also be considered. 
In conclusion, we show that liver fibrosis and cirrhosis is already present at a very 
young age. In mild patients with prominent neurological features, liver disease develops 
more slowly and insidious. This study also suggests that ZSD patients are at increased 
risk to develop a HCC. These findings support rigorous monitoring for liver disease in all 
patients with a ZSD.   
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 Figure legends 
Figure 1, liver histology: 
A; Liver cirrhosis (Sirius Red Stain for collagen) in patient 7 at autopsy. B; 
Hepatocellular carcinoma (H&E staining) in patient 7 at autopsy. C; Liver cirrhosis 
(Sirius Red Stain for collagen) in patient 13 at autopsy. D; Portal inflammation (H&E 
staining) in patient 13 at autopsy. E; Hepatocytes with many glycogenated nuclei (H&E 
staining) in patient 13 at autopsy. 
 
Figure 2, liver histology: 
A and B from patient 4 at the age of 1.5 years and C and D same patient at the age of 4.5 
year. A; Azan staining with periportal and pericellular fibrosis (blue). B; H&E staining 
with portal sclerosis and minimal portal inflammation (arrow). Some hepatocytes 
demonstrated glycogenated nuclei (circles). asterisk (*) shows ballooning. C; Azan 
staining with periportal and pericellular fibrosis (blue). D; H&E staining with lobular 
inflammation (arrow) and several hepatocytes with glycogenated nuclei (circles).  
 
Figure 3, Liver electron microscopy: 
A; Angulate lysosome of patient 5 at the age of 6 years. B; Import of labeled peroxisomal 
thiolase of patient 5 at the age of 4 years, i.e. functional peroxisomes (arrow) that are 
absent in many other hepatocytes. Import of labeled peroxisomal alanine glyoxylate 
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 aminotransferase (C) and thiolase (D) in patient 6 at the age of 7.5 years. Gold particles 
are seen in organelles with the morphology of lysosomes (arrows), not within 
peroxisomes. Catalase in these livers is in the cytoplasm, not in peroxisomes. 
Peroxisomal enzymes in lysosomal structures were also reported in patient 8 ((Roels et al. 
2003). Other larger organelles are mitochondria showing their cristae but no gold label 
(courtesy of Marc Espeel, Ghent University).  
.   
Additional Figure 1, liver light microscopy: 
A; (patient 4 at 4.5 years) Immunostaining of alanine glyoxylate aminotransferase. 
Positive in cytoplasm and some nuclei. There is no catalase immunoreactivity in the 
peroxisomes. Crystal of cytoplasmic AGT is seen as a small rod (arrow). B; (patient 4 at 
4.5 years) Immunostaining of catalase. Positive in all hepatocyte nuclei and cytoplasm 
but not within peroxisomes. C, D; (patient 5 at 4 years) Immunostaining for catalase. 
Positive in cytoplasm and few peroxisomes (arrow), i.e peroxisomal mosaicism. 
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Table 1: Liver related symptoms at time of liver biopsy/autopsy of 13 patients with a Zellweger spectrum disorder
Patient Gender PEX mutation
Zellweger 
severity score 1
Age at 
biopsy, yr
Current age 
or age at 
death, yr
Cause of 
death
Presence of 
cirrhosis/HCC
Prolonged 
neonatal 
jaundice
Hepato-
megaly
Spleno-
megaly
Portal 
hypertension Ascites
Coagulation 
defects
Variceal 
bleeding
1 m PEX12 p.S320F  + p.S320F 0.25 7 # RF — nm + — — — + —
2 f PEX1 p.I700Yfs*42 + p.G843D 19 0.5 14 — + + — — — + —
3 f PEX1 p.G843D + del exon 19/20 1 6 # RF — — + — — — + —
4 f PEX1 p.G843D + p.L879S 11 1.5 — nm + — — — nm —
4.5 22 — — — — — nm —
5 m PEX1 p.G843D + p.G843D 11 2 — + + + — — nm —
4 — nm nm — — nm —
6 27 nm nm — — + —
6 f PEX1 p.G843D + p.G843D 10 5 — — — — — — nm —
7.5 20 — — — — — nm —
7 f PEX26 p.R98W + p.R98W 36* 36 # RF + — — — — — + —
8 m PEX1 p.G843D 39 59 — nm — nm — — nm —
9 f PEX1 p.G843D + p.S190X 0.2 0.5 # LF + + + nm nm + —
10 m PEX1 p.G843D + p.G843D 0.25 1 # RF — + + + — — + —
11 f PEX1*** 0.2 — + + + nm nm + —
0.6* 0.6 # RF — + + nm nm +** —
12 f PEX1 p.G843D + p.G843D 1.5 1.5 # RF — nm + nm nm nm + —
13 f PEX1 p.G843D + p.S190X 7.5 + — + + — — + —
18.5* 18.5 # LF + — + + + + —
# deceased,  — = absent, + = present, *autopsy, **intracranial hemorrhage, ***complementation group (mutation unknown)
1Because of the retrospective character of the study, we were unable to determine the severity score in all  patients. Maximum score is 30 (most severe phenotype)
f=female, LF= liver failure, m=male, nm=not mentioned, RF= respiratoiry failure, yr=year
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Table 2: Findings at autopsy and/or liver biopsy of 13 patients with a Zellweger spectrum disorder
Patient Gender
Age at 
biopsy, 
 yr
Current 
age/age at 
death, yr
Medication 
use Steatosis Inflammation Bilirubinostasis Siderosis 
Copper 
accumulation
Glycogenated 
nuclei
Abnormal bile 
duct epithelium Perisinusoidal Periportal Pericellular Bridging Miscellaneous Peroxisomes
Angulate 
lysosomes
1 m 0.25 7 # vit D/K - - - + (grade I) - - + + + - <50% absent +
2 f 0.5 14 vit D/K - lobular (mild) - - - - - - + + - absent +
3 f 1 6 # vit E, DHA/AA - - - + (grade I) - - - + - + <50% absent +
4 f 1.5 - portal (moderate) - - - + + + + + <50% mozaik +
4.5 22 vit A/D/E - lobular (mild),    
portal (moderate)
- - - - + + + + <50% absent +
5 m 2 - portal (mild) - - - - + + + + >50% Steatosis on EM mozaik nd
4 - portal (mild) - - - - - + + + <50% Fibrosis on EM mozaik +
6 27 vit D/E/K - portal (mild) - - - - - Hepatic stellate-
cell l ipidosis
mozaik +
6 f 5 - - - - - + - + + + <50% Steatosis on EM absent +
7.5 20 vit D/E/K - lobular (mild),    
portal (severe)
- - - + - + + + <50% mozaik +
7 f 36* 36 # vit D, 
DHA/AA, 
ferro, urso
- portal (mild) - - - + - + + - >50% Cirrhosis, HCC nd +
8 m 39 59 - - - - - - - - - - - Hepatoportal 
sclerosis
mozaik +
9 f 0.2 0.5 # vit D/K, 
DHA/AA, 
urso, 
lactulose
- - + (canalicular) - - + - absent -
10 m 0.25 1 # DHA/AA - lobular (mild) - - - - - - + + <50% absent +
11 f 0.2 - lobular (mild) + (canalicular) + (grade I) - - - - + - - absent -
0.6* 0.6 # vit K - portal (mild) + (canalicular) - - - - + - - - Hepatoportal 
sclerosis
absent -
12 f 1.5 1.5 # vit K - portal (mild) - - - + + - + + - absent +
13 f 7.5 Cirrhosis on EM absent +
18.5* 18.5 # vit D/E/K, 
cholic acid
- lobular (mild),     
portal (mild)
+ (canalicular 
and ductular)
+ (grade I) + + - + + - >50% Cirrhosis, 
Dysplastic 
nodule
mozaik +
# deceased, *autopsy,  ̶  = absent, + = present. DHA/AA=docosahexaenoic acid/arachidonic acid, EM= electron microscopy, f=female, ferro=ferrous fumarate, HCC=hepatocellular carcinoma, m=male, nd=not determined, urso=ursodeoxycholic acid
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